Drug intelligence / Profile preview

Ferigun

Development stage: Unknown
Lead developer: Medimet Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

**Ferigun** is a timed-release oral fixed-dose haematinic capsule marketed by Medimet Pharmaceuticals. It contains ferrous sulfate and folic acid and is used for treatment and prophylaxis of iron and folic acid deficiency, particularly during pregnancy and lactation. The delayed-release formulation is designed to reduce gastric iron release and support intestinal iron absorption; iron replenishment supports hemoglobin production, while folic acid supports DNA synthesis and erythropoiesis. ([medimetpharma.com](https://medimetpharma.com/ferigun/))

Brand names: Ferigun
Other names: ferrous sulfate + folic acid

Targets

DHFR (Dihydrofolate reductase)

Beyond the preview

Go deeper on Ferigun.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ferigun.

Explore the full profile